Medical professionals are urging all Americans six months of age and older to receive the seasonal flu vaccine after an atypical early increase in cases has been observed on the West Coast. The surge is linked to the dominant H1N1 strain, which this year carries a new mutation identified as G155E.
New H1N1 mutation raises concerns for younger patients
H1N1, the virus responsible for the 2009 swine‑flu pandemic, is a standard component of the current 2026‑2027 flu vaccine. Scientists note that the G155E change may reduce the protection offered by prior infection or vaccination against earlier versions of the virus. Dr. Jennifer Duchon, a pediatric infectious‑disease specialist at Mount Sinai Children’s Hospital in New York, explained that younger individuals have had less exposure to this specific strain, which could lead to more severe outcomes for that age group. Her hospital has already begun to see flu cases consistent with the trend.
Immunologists caution that antibodies generated from last year’s flu season—when H3N2 was dominant—do not recognize the new mutation as effectively, particularly in teenagers and young adults, according to Jeanne Marrazzo, chief executive of the Infectious Diseases Society of America. While the studies are small, they highlight a potential “immunological gap” that could affect younger populations.
Vaccination rates have slipped as flu activity climbs
Data from market‑research firm IQVIA show that roughly 58 million American adults received a flu shot last season, a drop of more than 20 % from the near‑75 million in the 2019‑20 season, the last pre‑COVID‑19 baseline. Childhood vaccination rates have also fallen, with about half of children getting the shot compared with over 60 % in 2019‑20.
The American Medical Association continues to recommend vaccination for everyone six months and older. The current vaccine, approved by the FDA in August, targets H1N1, H3N2 and one influenza B virus. Scott Hensley, a microbiologist at the University of Pennsylvania, said two of the three vaccine components match circulating strains well, but the H1N1 mutation could compromise antibody response in younger people, making early vaccination advisable.
Manufacturers such as GSK, Sanofi, CSL’s Seqirus unit, AstraZeneca (which offers the FluMist nasal spray) and Moderna (which provides an mRNA flu vaccine) report demand comparable to the previous year. Two pharmacists speaking to Reuters indicated that uptake has not risen markedly despite the early warning.
Public‑health messaging and geographic shift
Historically, flu activity begins in the Southern United States and moves northward. This season, however, the initial rise is coming from the West Coast, where positive test rates reported to the CDC reached 10.7 % last week—far above the 0.5 % recorded a year earlier. Nationally, positive tests sit at a 10‑year high for this point in the season at 5 %, with peak levels typically around 30 %.
Epidemiologist Caitlin Rivers of Johns Hopkins University noted the lack of a clear explanation for the west‑to‑east pattern and suggested the new H1N1 mutation or the previous season’s focus on H3N2 could be factors. The CDC’s data also show elevated activity in eight Southern states, including Florida and South Carolina.
Public‑health communication has been affected by policy changes. Health Secretary Robert F. Kennedy Jr., known for anti‑vaccine activism, has reduced promotion of flu shots and overhauled childhood vaccine schedules. The CDC withdrew its recommendation for most children at the start of 2025, a decision currently on hold after a court intervention, and also paused its 2025 ad campaign for flu vaccination. Pediatric infectious‑disease expert Paul Offit attributes part of the decline in vaccination rates to these policy shifts and to statements from the Health Secretary.
When asked about current messaging, HHS spokesperson Emily Hilliard directed inquiries to the CDC’s “Respiratory Illness Season Toolkit,” which reiterates that vaccination remains the most effective tool to prevent serious flu illness.
Given the early rise in cases, the presence of a novel H1N1 mutation, and the observed dip in vaccination coverage, health officials stress that getting the flu shot promptly is the best strategy to protect individuals—especially younger people—against potentially severe disease.
Mitchell Landsberg is a Senior Technology Correspondent at News Raise. He covers consumer electronics, artificial intelligence, software developments, and digital privacy trends.
